Dr. Terashima on Bursectomy for Subserosal and Serosal Gastric Cancer

Masanori Terashima, MD, PhD, FACS
Published: Monday, Jan 23, 2017



Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

In Japan, since the 1950s, bursectomy was standard treatment for patients with advanced gastric cancer. However, due to negative reports, omentectomy became the new standard until a small, randomized phase II study was performed comparing bursectomy with non-bursectomy.

According to the trial, bursectomy seems to improve survival outcomes. However, due to the small sample size, researchers could not detect a significant enough difference between the 2 arms.
 


Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

In Japan, since the 1950s, bursectomy was standard treatment for patients with advanced gastric cancer. However, due to negative reports, omentectomy became the new standard until a small, randomized phase II study was performed comparing bursectomy with non-bursectomy.

According to the trial, bursectomy seems to improve survival outcomes. However, due to the small sample size, researchers could not detect a significant enough difference between the 2 arms.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x